vs
Ispire Technology Inc.（ISPR）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
Ispire Technology Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.0倍（$20.3M vs $19.6M），Ispire Technology Inc.净利率更高（-32.5% vs -177.4%，领先144.9%），STANDARD BIOTOOLS INC.同比增速更快（-11.5% vs -51.5%），Ispire Technology Inc.自由现金流更多（$-4.0M vs $-23.1M），过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-12.2% vs -17.8%）
Ispire科技是一家专注于先进雾化硬件及配套耗材研发、生产与销售的全球化科技企业，主要服务尼古丁及合法大麻消费市场，下设硬件、品牌大麻产品两大核心业务板块，覆盖北美、欧洲、亚太等核心市场，为B端合作商及终端用户提供合规创新的雾化解决方案。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
ISPR vs LAB — 直观对比
损益表 — Q2 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.3M | $19.6M |
| 净利润 | $-6.6M | $-34.7M |
| 毛利率 | 17.1% | 48.5% |
| 营业利润率 | -33.9% | -168.5% |
| 净利率 | -32.5% | -177.4% |
| 营收同比 | -51.5% | -11.5% |
| 净利润同比 | 17.4% | -28.8% |
| 每股收益（稀释后） | $-0.12 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $20.3M | — | ||
| Q3 25 | $30.4M | $19.6M | ||
| Q2 25 | $20.1M | $21.8M | ||
| Q1 25 | $26.2M | $40.8M | ||
| Q4 24 | $41.8M | — | ||
| Q3 24 | $39.3M | $22.1M | ||
| Q2 24 | $37.3M | $22.5M | ||
| Q1 24 | $30.0M | $45.5M |
| Q4 25 | $-6.6M | — | ||
| Q3 25 | $-3.3M | $-34.7M | ||
| Q2 25 | $-14.8M | $-33.5M | ||
| Q1 25 | $-10.9M | $-26.0M | ||
| Q4 24 | $-8.0M | — | ||
| Q3 24 | $-5.6M | $-26.9M | ||
| Q2 24 | $-3.5M | $-45.7M | ||
| Q1 24 | $-5.9M | $-32.2M |
| Q4 25 | 17.1% | — | ||
| Q3 25 | 17.0% | 48.5% | ||
| Q2 25 | 12.3% | 48.8% | ||
| Q1 25 | 18.2% | 48.4% | ||
| Q4 24 | 18.5% | — | ||
| Q3 24 | 19.5% | 54.9% | ||
| Q2 24 | 28.3% | 46.1% | ||
| Q1 24 | 20.4% | 53.1% |
| Q4 25 | -33.9% | — | ||
| Q3 25 | -8.9% | -168.5% | ||
| Q2 25 | -72.7% | -118.1% | ||
| Q1 25 | -40.4% | -80.8% | ||
| Q4 24 | -17.6% | — | ||
| Q3 24 | -13.4% | -120.9% | ||
| Q2 24 | -9.2% | -134.5% | ||
| Q1 24 | -18.8% | -132.2% |
| Q4 25 | -32.5% | — | ||
| Q3 25 | -10.7% | -177.4% | ||
| Q2 25 | -73.4% | -153.7% | ||
| Q1 25 | -41.5% | -63.8% | ||
| Q4 24 | -19.1% | — | ||
| Q3 24 | -14.2% | -122.0% | ||
| Q2 24 | -9.4% | -203.3% | ||
| Q1 24 | -19.7% | -70.6% |
| Q4 25 | $-0.12 | — | ||
| Q3 25 | $-0.06 | $-0.09 | ||
| Q2 25 | $-0.26 | $-0.09 | ||
| Q1 25 | $-0.19 | $-0.07 | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.10 | $-0.07 | ||
| Q2 24 | $-0.07 | $-0.12 | ||
| Q1 24 | $-0.11 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.6M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-7.7M | $399.7M |
| 总资产 | $84.4M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $17.6M | — | ||
| Q3 25 | $22.7M | $129.4M | ||
| Q2 25 | $24.4M | $158.6M | ||
| Q1 25 | $23.5M | $150.9M | ||
| Q4 24 | $34.4M | — | ||
| Q3 24 | $37.7M | $210.6M | ||
| Q2 24 | $35.1M | $269.8M | ||
| Q1 24 | $39.5M | $287.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
| Q4 25 | $-7.7M | — | ||
| Q3 25 | $-1.8M | $399.7M | ||
| Q2 25 | $604.7K | $424.5M | ||
| Q1 25 | $14.8M | $454.6M | ||
| Q4 24 | $24.2M | — | ||
| Q3 24 | $30.7M | $489.3M | ||
| Q2 24 | $34.5M | $510.3M | ||
| Q1 24 | $35.9M | $577.3M |
| Q4 25 | $84.4M | — | ||
| Q3 25 | $96.4M | $539.6M | ||
| Q2 25 | $102.2M | $557.0M | ||
| Q1 25 | $115.7M | $579.6M | ||
| Q4 24 | $132.0M | — | ||
| Q3 24 | $129.0M | $681.5M | ||
| Q2 24 | $122.6M | $708.7M | ||
| Q1 24 | $108.0M | $777.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.0M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-4.0M | $-23.1M |
| 自由现金流率自由现金流/营收 | -19.9% | -118.1% |
| 资本支出强度资本支出/营收 | 0.3% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-14.2M | $-111.1M |
8季度趋势，按日历期对齐
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-1.2M | $-22.2M | ||
| Q2 25 | $4.7M | $-20.7M | ||
| Q1 25 | $-12.5M | $-30.3M | ||
| Q4 24 | $-3.2M | — | ||
| Q3 24 | $3.6M | $-27.9M | ||
| Q2 24 | $-1.4M | $-39.0M | ||
| Q1 24 | $3.4M | $-62.5M |
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-1.2M | $-23.1M | ||
| Q2 25 | $3.7M | $-22.6M | ||
| Q1 25 | $-12.7M | $-35.3M | ||
| Q4 24 | $-3.2M | — | ||
| Q3 24 | $3.3M | $-30.1M | ||
| Q2 24 | $-2.2M | $-41.0M | ||
| Q1 24 | $3.3M | $-63.3M |
| Q4 25 | -19.9% | — | ||
| Q3 25 | -3.9% | -118.1% | ||
| Q2 25 | 18.6% | -103.6% | ||
| Q1 25 | -48.4% | -86.6% | ||
| Q4 24 | -7.7% | — | ||
| Q3 24 | 8.5% | -136.4% | ||
| Q2 24 | -5.9% | -182.2% | ||
| Q1 24 | 10.9% | -138.9% |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.0% | 4.5% | ||
| Q2 25 | 4.8% | 8.7% | ||
| Q1 25 | 0.7% | 12.4% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.7% | 10.2% | ||
| Q2 24 | 2.0% | 8.6% | ||
| Q1 24 | 0.3% | 1.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ISPR
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
